西洛他唑治疗脑出血:靶向硬脑膜淋巴管
本研究在小鼠胶原酶诱导的脑出血(ICH)模型中,口服临床等效剂量西洛他唑,于ICH后3小时或3天开始给药,均可增强硬脑膜淋巴管覆盖与功能,减少血肿体积、神经元损伤、突触丢失及长期神经功能缺损。西洛他唑未加重初始出血或血肿扩大,支持其临床转化并为正在进行的II期随机试验提供依据。
要点
- 口服西洛他唑可促进硬脑膜淋巴管重塑和引流,加速血肿消退。
- ICH后3小时或3天启动西洛他唑治疗均改善神经功能结局。
- 西洛他唑未增加血肿体积或诱发血肿扩大。
核心结论
- 西洛他唑通过促进硬脑膜淋巴管重塑和引流,促进ICH后血肿消退和神经功能恢复。
- 西洛他唑治疗不加重实验性ICH的初始出血或血肿扩大。
研究设计与样本
- 研究采用小鼠胶原酶注射诱导的微血管破裂ICH模型。
- 西洛他唑以临床等效剂量口服给药,在不同时间点及不同疗程给予。
- 在健康小鼠体内和离体脑膜中检查促淋巴管生成效应。
主要发现
- ICH后3小时或3天启动口服西洛他唑均增强硬脑膜淋巴管覆盖和功能。
- 西洛他唑治疗减少血肿体积、神经元损伤、突触丢失和长期神经功能缺损。
- 西洛他唑增加离体脑膜中CD31+PDPN+淋巴管内皮细胞,诱导硬脑膜淋巴管增生,增强健康小鼠淋巴引流。
- 预处理和延迟治疗均不增加血肿体积,反而改善ICH结局。
临床怎么用
- 西洛他唑可能作为促进ICH后血肿清除和神经恢复的候选治疗。
- 临床等效剂量口服给药具有转化潜力,支持进一步临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The meningeal lymphatic system contributes to hematoma resolution and neurological recovery after intracerebral hemorrhage (ICH). We previously demonstrated that intraperitoneal cilostazol administration promotes dural lymphatic growth and enhances clearance of intracerebrally injected red blood cells; however, the antiplatelet effects of cilostazol raise safety concerns in ICH, potentially limiting clinical translation. Here, we evaluated whether oral cilostazol at clinical-equivalent doses in mice enhances dural lymphatic function and improves outcomes after ICH. METHODS: ICH was induced by collagenase injection to model microvascular rupture. Cilostazol was orally administered to ICH mice at clinically equivalent doses, given at different time points and for varying durations. Prolymphangiogenic effects of cilostazol were examined in healthy in vivo and ex vivo meninges. Flow cytometry and immunofluorescence were performed to assess lymphatic endothelial cell proliferation and dural lymphatic remodeling. Lymphatic function was evaluated by in vivo live imaging and histological analysis of fluorescent tracer drainage. Short- and long-term histopathologic and behavioral outcomes were also evaluated. RESULTS: Oral cilostazol treatment initiated either 3 hours or 3 days after ICH enhanced dural lymphatic coverage and function, accompanied by reduced hematoma volume, neuronal injury, synapse loss, and long-term neurological deficits. Cilostazol increased CD31+PDPN+ lymphatic endothelial cells in ex vivo meninges, induced dural lymphatic hyperplasia, and enhanced lymphatic drainage in healthy mice. Both pretreatment and delayed treatment of cilostazol did not increase hematoma volume but rather improved ICH outcomes. CONCLUSIONS: By promoting dural lymphatic remodeling and drainage, cilostazol facilitates hematoma resolution and neurological recovery after ICH. Cilostazol treatment does not exacerbate initial bleeding or provoke hematoma expansion in the experimental ICH. These findings support clinical translation and provide mechanistic and dosing rationale for an ongoing phase II randomized trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT06504576).
引用
- Lan CK, Chen WR, Hsieh YC, et al. Cilostazol Treatment for Intracerebral Hemorrhage: Targeting Dural Lymphatics. Stroke. 2026. PMID: 42689324. doi:10.1161/STROKEAHA.126.055192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。